BestHealth4U’s Post

Zika virus against cancer: Brazilian innovation impresses the world! We are thrilled to announce that VYROBIO will be representing Brazil at the BIO International Convention, one of the world's largest biotechnology fairs, taking place next week in the USA. This is a significant milestone for Brazilian biotechnology. Founded by researchers from USP, VYROBIO was the only company selected among 50 biotechs to occupy the "Stadium" — a space reserved for the most promising companies at the convention. This recognition highlights the excellence and innovation of Brazilian research on the international stage. Vyro Biotherapeutics, supported by Sthorm, has gained notoriety for developing a safe, lab-modified version of the Zika virus capable of destroying central nervous system tumors. This breakthrough represents a revolution in the treatment of certain types of cancer. Vyro Biotherapeutics' participation in the BIO International Convention was featured in Folha de S.Paulo's Painel column written by Diego Felix . You can read the full article at the link below. Let's discuss: How do you see the future of Brazilian biotechs on the global stage? Share your thoughts in the comments! #Sthorm #VyroBiotherapeutics #PeopleAndPlanet #FindTheOthers https://lnkd.in/dTUJbz6j

#LLAI In July 2021, LungLife AI raised £17m at 176p in an IPO. Since then, this developer of next generation early stage lung cancer tests has hardly put a foot wrong. Yet despite the success, its shares presently languish at 30p. Equivalent to a modest £9.2m Mrkcap, augmented by net funds in the bank and a cash runway until April 2025. Elsewhere, the Board has hit its targets, cut costs where necessary, and importantly validated the accuracy & real-world performance of this patented technology. Indeed its flagship LungLB blood test has been independently proven to significantly improve the detection of difficult to diagnose small indeterminate lung nodules (ie <15mm in size). Delivering an 81% PPV, alongside outperforming the current standard-of-care (re PET scans & Mayo Nodule Calculator tools). The key question now facing investors is how much is #LLAI's unique diagnostics platform worth? At the last count in Jan’24 (ie pre fund raise), house broker Investec had a Target Price of 221p/share. Sure this may have slipped slightly after March’s $2.28m top up fund raise at 35p (re dilution).   Yet equally compared to today's valuation, there still appears to be plenty of upside potential, with Investec forecasting revenues of $4.3m and $8.0m respectively for this year & next. Ok, but what could be the catalyst for a re-rating? Well this is where it gets even more interesting. You see the LungLB blood test has already demonstrated its cost effectiveness and been granted a Medicare reimbursement code of $2,030/unit. CEO Paul Pagano adding “[We will soon] initiate our Early Access Program, submit forms for Medicare coverage consideration, and start the process of considering all strategic options to get the LungLB test into the hands of patients who need it most.” Here, I would not be too surprised to see LungLife AI ultimately team up with a much larger medical diagnostics firm (eg Roche, Thermo Fisher, Natera, etc) in order to accelerate the commercialisation process. Which hypothetically could be anytime over the next 12 months.

BeCapio, founded by a collaboration between Shaare Zedek Scientific (Madait) Zedek and The Trendlines Group, with funding from the Israel Innovation Authority רשות החדשנות, is working to improve the lives of those dealing with fecal incontinence.   More than 8% of the adult population globally suffers from fecal incontinence, usually as a result of childbirth trauma, spinal injuries, cancer, colon surgeries or other pelvic floor disorders, says Gil Senesh, co-founder and CEO of BeCapio. This condition, usually starting in middle-age, has a detrimental impact on the quality of life, and effective treatments are lacking.   The collaboration initiated and led by Dr. Dan M. Livovsky and Dr. Yossi Lysy, is changing this, as it brings together a top-notch development team with deep clinical understanding that has developed a novel treatment. The solution is a non-invasive patch device that combines multimodal therapies to support anal function. They will soon be starting a clinical study. #TTOspinoff #startupinnovation

🔬 CAR T-cell therapy further explored 🔬 For a long time, the perception has been that CAR T-cell therapy has little potential in the treatment of solid tumors. However, a recent publication showed that CAR T-cell therapy could have effect in solid tumors. The effect is still limited but there is already follow-up research that gives reason to think that future prospects are better. Workstream lead Cell and Gene therapy, John Haanen, is leader of the immunotherapy research theme and program director of the Center for Cell Therapy at our partner, the Antoni van Leeuwenhoek. He describes the developments in the world of CAR T-cells in the article below. 👇

✔ HistoSonics, Inc., who develop a histotripsy treatment for liver tumor procedures, completed an oversubscribed Series D financing round worth proceeds of $102 million to support its Edison system through clinical trials and commercialisation. ⭐ Mike Blue, president & CEO, commented: "This funding will accelerate key projects designed to enhance core technical capabilities impacting current and future platforms, and support collaboration with physicians and researchers studying innovative ways to use histotripsy’s unique mechanism of action to improve patient outcomes." 🔗 Learn more: https://lnkd.in/degnHhSi 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/d7MHCE-5 #MedicalDevices #MedicalDevice #MedicalEquipment #HealthTech #GuidedSolutions #ExecutiveSearch

The investment in BrainZell which was led by Industrifonden and where we at Norrsken Accelerate participated made headlines in Impact Loop. 📄 Based on decade long research at Karolinska Institutet the founders Petra Szeszula, PhD and Robin Pronk, PhD have developed a process for making organoids such as mini-brains from stem cells.🧠 Using these organoids, Pharmaceutical companies not only can cut the need for animal testing when developing new drugs but also significantly cut the testing phase from years to months. This has the potential to accelerate the discovery of cures for Alzheimers, epilepsy, and other neurological diseases. Speaking about a potential impact unicorn!🦄 https://lnkd.in/dX-RNTA9

Exscientia platform uses #generativeAI models and the scalability and flexibility of #AWS to securely, quickly, and efficiently #design #drug candidates that aim to better target specific #diseases and #patients, with the goal of #accelerating early #drugdevelopment | https://lnkd.in/egGGYY9n

Cool news in the longevity industry! LongeVC has joined Rubedo Life Sciences $40M Series A round to help bring anti-aging therapeutics to clinical trials. Rubedo is a California-based biotech, founded by Marco Quarta and Mark Gallop which develops first-in-class therapies targeting age-driving cells, including senescent cells. The company plans to use funding to advance its lead candidate RLS-1496 into Phase 1 clinical trial for chronic atopic dermatitis and chronic psoriasis. Senescence describes a process when a cell ages and permanently stops dividing but does not die, like it should in a normal cell cycle. Basically, it becomes a “zombie” cell. Senescence increases with age and when the number of zombie cells reaches a critical mass, they cause chronic inflammation and damage, leading to fibrosis and tissue degeneration which drive many age-related diseases. Rubedo uses its proprietary drug discovery platform ALEMBIC™ to engineer a broad portfolio of novel first-in-class small molecules designed to selectively target various types of senescent cells. So the platform is capable of producing medicines for many age-related diseases, such as pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. ALEMBIC™ is enabled by artificial intelligence (AI). Using single-cell RNA sequencing and other omics data, Rubedo utilized its proprietary database, which contains terabytes of internally-generated tissue analysis, and ALEMBIC’s AI capabilities to develop senescence signatures and profile senescent cells in clinical samples of diseased tissues. Overall, this is a powerful platform technology, and the company has a great leadership team, so I am confident about our participation in this endeavor. On the financial side, we are in a good company too, as the new round is led by world-class investors, including Khosla Ventures Ahren Innovation Capital, Hevolution Foundation , R42 Group, Modi Ventures Shanda Group Refactor Capital, IAG and others. #agingresearch #senescence #longevity #drugdiscovery Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI

Early-stage angel investor Karna D Shinde has made an undisclosed investment in Navaux, an innovative life science company based in Arkansas, USA. Navaux is at the forefront of early cancer detection and treatment monitoring with its groundbreaking blood test, ACTIVH. Developed through extensive preclinical studies, ACTIVH can predict cancer up to 3-4 years before onset, allowing individuals to make proactive lifestyle changes that may prevent the disease. The noninvasive, quick, and straightforward test involves a simple blood draw to detect elevated Hepsin levels, which are indicative of tumors. "ACTIVH is a more affordable and accessible alternative to traditional methods, making proactive health management available to a broader audience," the company stated. Beyond early detection, ACTIVH is crucial for monitoring ongoing cancer treatments. By tracking Hepsin levels, it offers real-time insights into the effectiveness of therapies like chemotherapy and radiation. A drop in Hepsin levels suggests successful treatment, while an increase indicates the need for alternative approaches. "Early cancer detection significantly boosts survival rates. Navaux's ACTIVH offers a vital advantage for patients and their families," said Karna D Shinde. India’s burgeoning health-tech sector is highlighted by Finance Minister Nirmala Sitharaman’s recent Union Budget 2024-25 announcement, which exempts three essential cancer treatment medicines from customs duty to enhance access. "This investment is pivotal in helping Navaux forge connections within the Indian healthcare industry as they prepare to introduce their cutting-edge solutions to this new market," Navaux commented. Shinde’s investment extends beyond financial backing; his strategic insights and hands-on approach are crucial for Navaux’s growth. Don Fowler, CEO of Navaux, noted, "Karna’s involvement has been transformative in advancing our technology and exploring new markets." Navaux is also preparing to present new preclinical and clinical data on the prognostic potential of circulating Hepsin at the American Association for Cancer Research (AACR), aiming to validate the ACTIVH test’s effectiveness and its potential to revolutionize cancer detection and treatment monitoring worldwide. #Navaux #CancerDetection #EarlyDetection #LifeSciences #HealthTech #Innovation #ACTIVH #AngelInvestment #HealthCare #PreclinicalStudies #CancerResearch #TechInHealthcare #MedicalInnovation #CancerTreatment #HealthManagement #IndiaHealthTech #AACR2024 #Oncology #HealthcareAdvancements #AllBoutCorps

One step closer to delivering liver tissue therapeutics to patients. SPRIND - Bundesagentur für Sprunginnovationen, Germany's Federal Agency for Disruptive Innovation, supports us in developing liver tissue therapeutics so that patients dealing with seriously impaired liver function can enjoy longer and healthier lives. Together with our clinical partners at CHARITE UNIVERSITATSMEDIZIN BERLIN, we have set ourselves the goal to replicate human liver tissue at scale. We will use 3D bioprinting to biofabricate human liver tissue that will ultimately be implanted into the patients' bodies. We are proud to make a major contribution to alleviate the global liver crisis and to have won SPRIND-Bundesagententur für Sprunginnovationen as a partner for this exciting journey.    About SPRIND - Bundesagentur für Sprunginnovationen    SPRIND invests in groundbreaking projects that shape the future and provide answers to the most pressing social, ecological and economic challenges of our time. The goal is to create new leapfrogging innovations made in Germany. In other words, products, services and systems that make our lives noticeably and sustainably better.  “Funke Tissue Engineering” is the latest innovation challenge by SPRIND and scouts for solutions that target the global organ shortage by creating artificial organ tissue.     #SPRIND #Cellbricks #Charité #FunkeTissueEngineering #ReplicatingHumanTissueAtScale #OrganCrisis #Longevity #TissueTherapeutics #3DBioprinting